Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK court upholds Pfizer’s main Lipitor patent
The ruling is the result of a lawsuit brought by the generic manufacturer Ranbaxy, which challenged two patents protecting Lipitor. The court ruled that a Ranbaxy generic would
The ruling is the result of a lawsuit brought by the generic manufacturer Ranbaxy, which challenged two patents protecting Lipitor. The court ruled that a Ranbaxy generic would
The double-blind, placebo-controlled phase II study will enroll a total of 480 healthy volunteers, who will be randomized to receive either vaccine or placebo. The treatment group will
Agvar Chemicals and Ranbaxy Laboratories supplied fexofenadine, the active ingredient in Allegra, to Barr during the development of the product. Barr then obtained FDA approval for the compound
This phase III trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Evamist. The primary endpoint is the reduction in the frequency
The single-dose phase II clinical trial will be conducted at hospitals in Massachusetts and California and is expected to enroll up to 150 patients with C difficile associated
In the collaboration with Arch, Codexis will apply its novel, cost-effective Molecular-Breeding technology to manufacture an undisclosed pharmaceutical compound. In the collaboration with Matrix, Codexis is to develop
tgAAC94 utilizes Targeted Genetics’ Adeno-Associated Viral (AAV) vector technology to deliver a DNA sequence encoding an inhibitor of TNF-alpha, a potent pro-inflammatory cytokine that plays a major role
Orphan products development grants are awarded by the FDA to encourage clinical development of products for use in rare diseases or conditions, usually defined as affecting less than
Valortim is a fully human antibody developed by Medarex’s UltiMAb human antibody development system that targets the bacillus anthracis protective antigen. The research, presented at the Infectious Diseases
MPC-0920 is an orally available, direct thrombin inhibitor. It is designed to address the clinical needs for rapid and predictable anticoagulant action, an improved therapeutic window, predictable patient